Abzena – San Diego Lusk Facility
Abzena - San Diego Lusk Facility
Speed to market is critical to the development of advanced medicines. As a large biopharma contract development and manufacturing organization (CDMO), Abzena drives the discovery and manufacturing of complex biologics and bioconjugates for its clients around the globe.
Challenges
Abzena’s rapid growth presented an urgent need to evolve into a fully integrated end-to-end biotherapeutic and antibody-drug conjugate (ADC) powerhouse. As a full-service provider of cGMP biotherapeutics, Abzena required equipment designed to support advanced therapies. They needed to sustain an accelerated pace without compromising on precision, quality or safety.
Solutions
Abzena developed five state-of-the-art facilities across North America and Europe outfitted with critical equipment to support the development and manufacture of advanced therapies with rapid speed. The San Diego Lusk Facility has 20,800 square feet of dedicated manufacturing space, including a quality control microbiology laboratory, a quality control analytical laboratory, stability chamber and staging warehouse space. This facility focuses on biologics drug substance development and manufacturing.
Visit the San Diego Lusk Facility
To support the 15,800 square feet of cGMP manufacturing space, Abzena integrated Labconco’s Logic®+ Class II, Type A2 Biosafety Cabinets (BSCs) into several key processes within the facility, including master cell bank preparation and inoculum preparation (initial thaw and expansion (ITE)). Labconco’s BSCs are engineered to operate within ISO 5 aseptic working conditions, providing superior user protection when working with biological materials. Logic+ BSCs offer controlled airflow, enhanced filter life and ergonomic considerations to maintain safety conditions crucial for sensitive processes.
Benefits
The expansion project has enabled Abzena to bolster its capabilities in biologics development and manufacturing, enhancing its ability to meet the growing demand for biopharmaceutical products. By incorporating Labconco’s Class II BSCs, Abzena can ensure the integrity and sterility of each biotherapeutic throughout the development process to deliver life-altering treatments with unprecedented speed and reliability.
Facility At-A-Glance
Biologics Drug Substance Development and Clinical & Commercial Scale Manufacturing
Comprehensive biologic process development for therapeutic proteins and recombinant vaccines, including antibodies, bispecifics and bifunctional immunotherapeutics
Robust analytical method development portfolio
MCB/WCB cGMP suite (Class 10,000) with ISO Class 5 (Class 100) BSCs
ISO Class 8 cGMP suites (class 100,000) - 50L, 200L, 500L, to 2000L
Biologic Quality Control Stability
Learn more about Abzena by visiting Abzena.com.
